KRT88P and hepatocellular carcinoma: A retrospective study from Hong Kong described a similar 10-year graft survival rate for 416 recipients of anti-HBc-positive grafts (76.8%) when compared to 548 recipients of anti-HBc-negative grafts (74.8%) and without any difference in graft dysfunction, recipient death, or hepatocellular carcinoma [58].